Corcept Therapeutics Inc (CORT): R&D Expense
$254.91M
Year ended 2025-12-31
$253.86M
Trailing 12 months to 2026-06-30
+24.8%
3-year compound annual growth
+17.3%
5-year compound annual growth
+32.4%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $254.91M | +3.2% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $246.89M | +33.9% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $184.35M | +40.7% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $130.99M | +15.0% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $113.86M | -0.8% | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | $114.76M | +28.9% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $89.02M | +18.3% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $75.25M | +86.4% | 2021-02-23, From 2018-01-01 |
| 2017-12-31 | $40.38M | +69.3% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $23.84M | +54.6% | 2019-02-26, From 2016-01-01 |
| 2015-12-31 | $15.42M | -16.1% | 2018-02-28, From 2015-01-01 |
| 2014-12-31 | $18.37M | -10.2% | 2017-03-06, From 2014-01-01 |
| 2013-12-31 | $20.47M | +45.4% | 2016-03-10, From 2013-01-01 |
| 2012-12-31 | $14.07M | -33.0% | 2015-03-13, From 2012-01-01 |
| 2011-12-31 | $21.00M | +10.8% | 2014-03-14, From 2011-01-01 |
| 2010-12-31 | $18.95M | +31.6% | 2013-03-15, From 2010-01-01 |
| 2009-12-31 | $14.40M | n/a | 2012-03-13, From 2009-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $254.91M | +3.2% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $53.20M | -24.8% |
| Collegium Pharmaceutical, Inc (COLL) | 2024-12-31 | $0 | n/a |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $117.31M | +43.8% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $85.84M | +16.1% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $106.23M | -2.4% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $607.16M | +20.0% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $96.85M | -13.2% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $750.00M | +7.4% |
Compare CORT, EBS, COLL, PCRX side by side · Screen every company in Pharmaceutical Preparations ↗